{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:54:27Z","timestamp":1793764467573,"version":"4.6.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["GNT1156446"],"award-info":[{"award-number":["GNT1156446"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020485","name":"Foundation for High Blood Pressure Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020821","name":"Monash Biomedicine Discovery Institute, Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.biopha.2022.114069","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T03:06:24Z","timestamp":1670468784000},"page":"114069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice"],"prefix":"10.1016","volume":"158","author":[{"given":"Yifang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Salimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad R.S.","family":"Broughton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon D.","family":"Ricardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"de Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrishan S.","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.114069_bib1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/ki.2011.368","article-title":"The contribution of chronic kidney disease to the global burden of major noncommunicable diseases","volume":"80","author":"Couser","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2022.114069_bib2","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1038\/s41598-018-27377-2","article-title":"Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study","volume":"8","author":"Zhou","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.114069_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jash.2015.01.005","article-title":"Basic science: hypertensive target organ damage","volume":"9","author":"Bidani","year":"2015","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.biopha.2022.114069_bib4","first-page":"866","article-title":"End organ damage in hypertension","volume":"107","author":"Schmieder","year":"2010","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.biopha.2022.114069_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","article-title":"Management of hypertension in chronic kidney disease","volume":"79","author":"Pugh","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2022.114069_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1524-6175.2005.04119.x","article-title":"Hypertensive heart disease","volume":"7","author":"Prisant","year":"2005","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.biopha.2022.114069_bib7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.semnephrol.2016.08.001","article-title":"Developing treatments for chronic kidney disease in the 21st century","volume":"36","author":"Breyer","year":"2016","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.biopha.2022.114069_bib8","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.2174\/13816128113199990477","article-title":"Mesenchymal stromal cell therapy for cardio renal disorders","volume":"20","author":"Reinders","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2022.114069_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-1797.2011.01501.x","article-title":"Mesenchymal stem cells in kidney inflammation and repair","volume":"17","author":"Wise","year":"2012","journal-title":"Nephrology"},{"key":"10.1016\/j.biopha.2022.114069_bib10","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.3390\/ijms23116035","article-title":"Enhancing the therapeutic potential of mesenchymal stromal cell-based therapies with an anti-fibrotic agent for the treatment of chronic kidney disease","volume":"23","author":"Li","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.114069_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114884","article-title":"Relaxin as an anti-fibrotic treatment: perspectives, challenges and future directions","volume":"197","author":"Samuel","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2022.114069_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2018.12.016","article-title":"Cardioprotective actions of relaxin","volume":"487","author":"Martin","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2022.114069_bib13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.drudis.2020.04.014","article-title":"Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target","volume":"25","author":"Bani","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2022.114069_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mce.2019.01.013","article-title":"Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): Rationale for future clinical trials","volume":"487","author":"Dschietzig","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2022.114069_bib15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1096\/fj.14-254789","article-title":"Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy","volume":"29","author":"Huuskes","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2022.114069_bib16","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/bph.15361","article-title":"Combining mesenchymal stem cells with serelaxin provides enhanced renoprotection against 1K\/DOCA\/salt-induced hypertension","volume":"178","author":"Li","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.114069_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112256","article-title":"Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive mice","volume":"144","author":"Li","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2022.114069_bib18","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.neuroimage.2009.10.002","article-title":"MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field","volume":"49","author":"Marques","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopha.2022.114069_bib19","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1161\/01.HYP.37.5.1199","article-title":"Gender differences in the regulation of blood pressure","volume":"37","author":"Reckelhoff","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2022.114069_bib20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/bph.13230","article-title":"Inflammasome activity is essential for one kidney\/deoxycorticosterone acetate\/salt-induced hypertension in mice","volume":"173","author":"Krishnan","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.114069_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","article-title":"Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity","volume":"63","author":"Feria","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2022.114069_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yjmcc.2017.10.006","article-title":"Echocardiographic evaluation of diastolic function in mouse models of heart disease","volume":"114","author":"Schnelle","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2022.114069_bib23","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jcmg.2019.01.044","article-title":"2- and 3-Dimensional myocardial strain in cardiac health and disease","volume":"12","author":"Voigt","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.biopha.2022.114069_bib24","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.21105\/joss.02343","article-title":"qMRLab: quantitative MRI analysis, under one umbrella","volume":"5","author":"Karakuzu","year":"2020","journal-title":"J. Open Source Softw."},{"key":"10.1016\/j.biopha.2022.114069_bib25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.crad.2016.02.013","article-title":"Assessment of myocardial fibrosis with T1 mapping MRI","volume":"71","author":"Everett","year":"2016","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.biopha.2022.114069_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10741-017-9627-2","article-title":"T1 mapping in cardiac MRI","volume":"22","author":"Radenkovic","year":"2017","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.biopha.2022.114069_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12968-016-0308-4","article-title":"Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review","volume":"18","author":"Haaf","year":"2016","journal-title":"J. Cardiovasc. Magn. Reson"},{"key":"10.1016\/j.biopha.2022.114069_bib28","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ajpath.2011.05.037","article-title":"Colony-stimulating factor-1 promotes kidney growth and repair via alteration of macrophage responses","volume":"179","author":"Alikhan","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2022.114069_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11906-017-0731-4","article-title":"DOCA-salt hypertension: an update","volume":"19","author":"Basting","year":"2017","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.biopha.2022.114069_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/HYPERTENSIONAHA.114.03594","article-title":"Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease","volume":"64","author":"Samuel","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2022.114069_bib31","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1038\/s41598-017-02916-5","article-title":"ML290 is a biased allosteric agonist at the relaxin receptor RXFP1","volume":"7","author":"Kocan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.114069_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yexcr.2017.10.004","article-title":"Serelaxin inhibits differentiation and fibrotic behaviors of cardiac fibroblasts by suppressing ALK-5\/Smad2\/3 signaling pathway","volume":"362","author":"Wu","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2022.114069_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063896","article-title":"Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-beta\/Smad3 signaling","volume":"8","author":"Sassoli","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.114069_bib34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/labinvest.2010.198","article-title":"Relaxin remodels fibrotic healing following myocardial infarction","volume":"91","author":"Samuel","year":"2011","journal-title":"Lab. Invest."},{"key":"10.1016\/j.biopha.2022.114069_bib35","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1111\/bph.15428","article-title":"Simultaneous targeting of oxidative stress and fibrosis reverses cardiomyopathy-induced ventricular remodelling and dysfunction","volume":"178","author":"Wang","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.114069_bib36","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1210\/en.2006-1324","article-title":"Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes","volume":"148","author":"Moore","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2022.114069_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/CIRCRESAHA.113.301646","article-title":"Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts","volume":"113","author":"Parikh","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2022.114069_bib38","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1038\/s41598-019-53867-y","article-title":"Relaxin reverses maladaptive remodeling of the aged heart through Wnt-signaling","volume":"9","author":"Martin","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2022.114069_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159872","article-title":"Collecting duct renin does not mediate DOCA-salt hypertension or renal injury","volume":"11","author":"Song","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2022.114069_bib40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1589\/jpts.27.303","article-title":"A review of deoxycorticosterone acetate-salt hypertension and its relevance for cardiovascular physiotherapy research","volume":"27","author":"Lee","year":"2015","journal-title":"J. Phys. Ther. Sci."},{"key":"10.1016\/j.biopha.2022.114069_bib41","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Blood pressure lowering treatment trialists' collaboration: effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.114069_bib42","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"issue":"7258","key":"10.1016\/j.biopha.2022.114069_bib43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2022.114069_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.yjmcc.2019.09.010","article-title":", Genetic ablation and pharmacological inhibition of immunosubunit \u03b25i attenuates cardiac remodeling in deoxycorticosterone-acetate (DOCA)-salt hypertensive mice","volume":"137","author":"Cao","year":"2019","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"2","key":"10.1016\/j.biopha.2022.114069_bib45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbrc.2017.05.011","article-title":"Knockout of immunoproteasome subunit \u03b22i ameliorates cardiac fibrosis and inflammation in DOCA\/Salt hypertensive mice","volume":"490","author":"Yan","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2022.114069_bib46","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/HYPERTENSIONAHA.112.202606","article-title":"Cytochrome P450 1B1 gene disruption minimizes deoxycorticosterone acetate-salt\u2013induced hypertension and associated cardiac dysfunction and renal damage in mice","volume":"60","author":"Jennings","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2022.114069_bib47","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.taap.2018.10.004","article-title":"Metformin attenuates cardiovascular and renal injury in uninephrectomized rats on DOCA-salt: Involvement of AMPK and miRNAs in cardioprotection","volume":"362","author":"Amara","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2022.114069_bib48","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1161\/HYPERTENSIONAHA.110.149815","article-title":"Lifetime overproduction of circulating angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling","volume":"55","author":"N.v.M. Santiago","year":"2010","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.biopha.2022.114069_bib49","doi-asserted-by":"crossref","first-page":"9793","DOI":"10.1038\/s41598-017-09470-0","article-title":"Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.biopha.2022.114069_bib50","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/j.1432-2277.2008.00742.x","article-title":"Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure","volume":"21","author":"Li","year":"2008","journal-title":"Transpl. Int."},{"issue":"2","key":"10.1016\/j.biopha.2022.114069_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5966\/sctm.2011-0015","article-title":"Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair","volume":"1","author":"Oskouei","year":"2012","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.biopha.2022.114069_bib52","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.2147\/DDDT.S85399","article-title":"Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway","volume":"9","author":"Zhou","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"issue":"32","key":"10.1016\/j.biopha.2022.114069_bib53","doi-asserted-by":"crossref","first-page":"11474","DOI":"10.1073\/pnas.0504388102","article-title":"Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction","volume":"102","author":"Amado","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.biopha.2022.114069_bib54","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.104.500447","article-title":"Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy","volume":"112","author":"Nagaya","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.biopha.2022.114069_bib55","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCIMAGING.108.835793","article-title":"Late gadolinium-enhancement cardiac magnetic resonance identifies postinfarction myocardial fibrosis and the border zone at the near cellular level in ex vivo rat heart","volume":"3","author":"Schelbert","year":"2010","journal-title":"Circ. Cardiovasc. Imaging"},{"issue":"1","key":"10.1016\/j.biopha.2022.114069_bib56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1161\/CIRCIMAGING.112.979815","article-title":"Role of transcytolemmal water-exchange in magnetic resonance measurements of diffuse myocardial fibrosis in hypertensive heart disease","volume":"6","author":"Coelho-Filho","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"issue":"22","key":"10.1016\/j.biopha.2022.114069_bib57","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study","volume":"322","author":"Levy","year":"1990","journal-title":"N. Engl. J. Med."}],"updated-by":[{"DOI":"10.1016\/j.biopha.2026.119143","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000}},{"DOI":"10.1016\/j.biopha.2026.119143","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000}}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:24:01Z","timestamp":1779794641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222014585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":57,"alternative-id":["S0753332222014585"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114069","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114069"}}